NCT04877756View on ClinicalTrials.gov

Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 19, 2021

Primary Completion Date

January 11, 2023

Study Completion Date

July 12, 2023

Conditions
Hypertrophic Scar
Interventions
DRUG

OLX10010

Lyophilized cake reconstituted with WFI and injected intradermally

Trial Locations (6)

19103

Paddington Testing Co, Inc., Philadelphia

20010

MedStar Health Research Institute, Washington D.C.

33173

Miami Dermatology & Laser Research, LLC, Miami

33176

Miami Plastic Surgery, Miami

44106

University Hospitals Cleveland Medical Center, Cleveland

48202

Henry Ford Health System, Detroit

Sponsors

Collaborators (1)

Alira Health
All Listed Sponsors
collaborator

Alira Health

OTHER

lead

Olix Pharmaceuticals, Inc.

INDUSTRY

NCT04877756 - Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery | Biotech Hunter | Biotech Hunter